# US 2022/0031762 A1 · Use of endothelial progenitor cells in rejuvenating the microvasculature, preventing aging and treating age-related diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031762 A1
- Document ID: US20220031762A1
- Status: Published application
- Kind: A1
- Application number: 17/461,094
- Filed: 2021-08-30
- Published: 2022-02-03
- Earliest claimed: 2019-02-28
- Assignees: Shenzhen University
- Applicants: Shenzhen University
- Inventors: Baohua LIU; Shimin SUN
- Web page: https://patentgrep.com/patent/US20220031762A1

## CPC

- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C12N 5/0692: {Stem cells; Progenitor cells; Precursor cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Use of endothelial progenitor cells in the manufacture of a medicament for rejuvenating neovascularization capacity, ameliorating aging features, preventing aging, extending lifespan, and/or treating progeria and/or age-related diseases. A method for rejuvenating neovascularization capacity, ameliorating aging features, preventing aging, extending lifespan, and/or treating progeria and/or age-related diseases, includes: administering a pharmaceutically effective amount of EPCs to a subject in need thereof.

## Claims

### Claim 1

Use of endothelial progenitor cells in the manufacture of a medicament for rejuvenating neovascularization capacity, ameliorating aging features, preventing aging, extending lifespan, and/or treating progeria and/or age-related diseases.

### Claim 2 (depends on 1)

Use according to claim 1, wherein the endothelial progenitor cells are CD133+ endothelial progenitor cells.

### Claim 3 (depends on 1)

Use according to claim 1, wherein the age-related diseases are cardiovascular diseases and/or osteoporosis.

### Claim 4 (depends on 3)

Use according to claim 3, wherein the cardiovascular diseases are atherosclerosis and/or heart failure.

### Claim 5 (depends on 1)

Use according to claim 1, wherein the progeria and/or age-related diseases are characterized by vascular endothelium dysfunction.

### Claim 6 (depends on 5)

Use according to claim 5, wherein the vascular endothelium dysfunction comprises: a loss of endothelial cells, reduced capillary density and defective neovascularization capacity.

### Claim 7 (depends on 5)

Use according to claim 5, wherein the vascular endothelium dysfunction is caused by progerin.

### Claim 8

A method for rejuvenating neovascularization capacity, ameliorating aging features, preventing aging, extending lifespan, and/or treating progeria and/or age-related diseases, comprising administering a pharmaceutically effective amount of EPCs to a subject in need thereof.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the age-related diseases are cardiovascular diseases and/or osteoporosis.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the age-related diseases are atherosclerosis and/or heart failure.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the EPCs are CD133+ EPCs.

### Claim 12 (depends on 8)

The method according to claim 8, wherein the age-related diseases are characterized by vascular endothelium dysfunction; particularly, the vascular endothelium dysfunction includes a loss of endothelial cells, reduced capillary density and defective neovascularization capacity.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the vascular endothelium dysfunction is caused by progerin.
